Heaney, L. G., Busby, J., Hanratty, C. E., Djukanovic, R., Woodcock, A., Walker, S. M., . . . Pavord, I. D. (2021). Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: A multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med.
Citación estilo ChicagoHeaney, Liam G., et al. "Composite Type-2 Biomarker Strategy Versus a Symptom–risk-based Algorithm to Adjust Corticosteroid Dose in Patients With Severe Asthma: A Multicentre, Single-blind, Parallel Group, Randomised Controlled Trial." Lancet Respir Med 2021.
Cita MLAHeaney, Liam G., et al. "Composite Type-2 Biomarker Strategy Versus a Symptom–risk-based Algorithm to Adjust Corticosteroid Dose in Patients With Severe Asthma: A Multicentre, Single-blind, Parallel Group, Randomised Controlled Trial." Lancet Respir Med 2021.